Format

Send to

Choose Destination
Clin Case Rep. 2017 Apr 24;5(6):891-893. doi: 10.1002/ccr3.969. eCollection 2017 Jun.

Obinutuzumab-induced serum sickness following salvage therapy for chronic lymphocytic leukemia.

Author information

1
Division of Malignant Hematology and Blood and Marrow Transplantation University of California San Francisco California.

Abstract

The incidence of serum sickness following treatment of CLL with obinutuzumab has not been fully characterized, but is likely rare. Consideration should be given to this diagnosis in appropriate circumstances so that effective corticosteroid therapy can be initiated to alleviate inflammatory symptoms and organ dysfunction in a timely manner.

KEYWORDS:

Chronic lymphocytic leukemia; monoclonal antibody; obinutuzumab; serum sickness

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center